摘要
[目的]探讨来氟米特(LEF)对环磷酰胺(CTX)治疗无效的狼疮肾炎(LN)的临床疗效及安全性。[方法]观察43例经CTX治疗无效、复发或因不良反应停用的狼疮肾炎患者经LEF治疗12个月前后临床和免疫指标的变化,并记录不良反应发生率。[结果]LEF治疗1个月后,尿蛋白明显减少,白蛋白增加,血肌酐降低,有19例肾功能不全病人治疗半年后肾功能恢复,治疗3～6个月时抗dsDNA抗体显著降低,SLEDAI明显降低,较治疗前相比差异均有显著性意义。治疗过程中共发生不良反应12例,不良反应发生率28%,而治疗前CTX治疗时不良反应发生率74.4%(32/43),两者比较差异有非常显著性意义(P<0.01)。[结论]LEF对CTX治疗无效的LN有显著疗效,其不良反应较小,患者耐受性较好。
[Objective] To discuss the efficacy and safety of treatment with Leflunomide for lupus nephritis（LN） failed from the treatment of cyclophosphamide.[Methods] Forty-three patients with LN,who had failed intermittent cyclophosphamide（CTX） intravenous treatment or had relapsed or withdraw because of adverse reactions,had received the LEF treatment for 12 months.The change of clinical efficacy and immunology indexes were assessed.And the occurrence ratio of adverse reaction was recorded.[Results] After one month of LEF treatment,the urine protein was significantly reduced,serum albumin increased,and anti-dsDNA antibody and SLEDAI decreased gradually after 3-6 months.The difference,compared with that of pre-treatment,was significant.The incidence of side-effects of LEF was less than that of pre-treatments（28% vs 74.4%）.[Conclusion] LEF treatment for refractory LN patients who had failed intermittent CTX is effective,the adverse events are not serious.
出处
《大连医科大学学报》
CAS
2010年第6期689-691,694,共4页
Journal of Dalian Medical University
